vs
Side-by-side financial comparison of CARRIAGE SERVICES INC (CSV) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $105.5M, roughly 1.7× CARRIAGE SERVICES INC). CARRIAGE SERVICES INC runs the higher net margin — 11.6% vs 1.6%, a 10.0% gap on every dollar of revenue. On growth, CARRIAGE SERVICES INC posted the faster year-over-year revenue change (8.0% vs 5.0%). Over the past eight quarters, CARRIAGE SERVICES INC's revenue compounded faster (1.0% CAGR vs -0.2%).
Jardine Cycle & Carriage Limited is the investment holding company of Jardines in Southeast Asia. It is currently 75% held by the conglomerate.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CSV vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $105.5M | $177.4M |
| Net Profit | $12.3M | $2.9M |
| Gross Margin | 34.8% | — |
| Operating Margin | 23.3% | 3.9% |
| Net Margin | 11.6% | 1.6% |
| Revenue YoY | 8.0% | 5.0% |
| Net Profit YoY | 24.5% | — |
| EPS (diluted) | $0.76 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $105.5M | $196.9M | ||
| Q3 25 | $102.7M | $179.5M | ||
| Q2 25 | $102.1M | $181.1M | ||
| Q1 25 | $107.1M | $168.9M | ||
| Q4 24 | $97.7M | $187.3M | ||
| Q3 24 | $100.7M | $168.6M | ||
| Q2 24 | $102.3M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $12.3M | — | ||
| Q3 25 | $6.6M | $5.4M | ||
| Q2 25 | $11.7M | $-4.8M | ||
| Q1 25 | $20.9M | $4.8M | ||
| Q4 24 | $9.9M | — | ||
| Q3 24 | $9.9M | $-143.5M | ||
| Q2 24 | $6.3M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 34.8% | 79.5% | ||
| Q3 25 | 35.3% | 80.9% | ||
| Q2 25 | 35.2% | 77.4% | ||
| Q1 25 | 35.3% | 79.7% | ||
| Q4 24 | 34.4% | 78.7% | ||
| Q3 24 | 35.2% | 76.9% | ||
| Q2 24 | 36.2% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 23.3% | 1.2% | ||
| Q3 25 | 17.0% | 3.5% | ||
| Q2 25 | 23.5% | 4.7% | ||
| Q1 25 | 29.5% | 1.2% | ||
| Q4 24 | 21.6% | 13.2% | ||
| Q3 24 | 22.7% | -82.8% | ||
| Q2 24 | 18.0% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 11.6% | — | ||
| Q3 25 | 6.4% | 3.0% | ||
| Q2 25 | 11.5% | -2.7% | ||
| Q1 25 | 19.5% | 2.8% | ||
| Q4 24 | 10.1% | — | ||
| Q3 24 | 9.8% | -85.1% | ||
| Q2 24 | 6.1% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.76 | $0.05 | ||
| Q3 25 | $0.41 | $0.12 | ||
| Q2 25 | $0.74 | $-0.11 | ||
| Q1 25 | $1.34 | $0.10 | ||
| Q4 24 | $0.62 | $0.38 | ||
| Q3 24 | $0.63 | $-3.11 | ||
| Q2 24 | $0.40 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $254.8M | $653.9M |
| Total Assets | $1.3B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $1.7M | $238.4M | ||
| Q3 25 | $1.2M | $246.3M | ||
| Q2 25 | $1.4M | $445.9M | ||
| Q1 25 | $4.6M | $493.6M | ||
| Q4 24 | $1.2M | $484.6M | ||
| Q3 24 | $1.3M | $453.8M | ||
| Q2 24 | $1.5M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $254.8M | $693.1M | ||
| Q3 25 | $242.1M | $727.2M | ||
| Q2 25 | $235.4M | $757.8M | ||
| Q1 25 | $223.1M | $798.5M | ||
| Q4 24 | $208.6M | $778.3M | ||
| Q3 24 | $198.1M | $749.6M | ||
| Q2 24 | $187.9M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.3B | $1.3B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.3B | $1.6B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $1.3B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.1M | — |
| Free Cash FlowOCF − Capex | $6.2M | — |
| FCF MarginFCF / Revenue | 5.9% | — |
| Capex IntensityCapex / Revenue | 7.5% | — |
| Cash ConversionOCF / Net Profit | 1.15× | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $14.1M | $43.7M | ||
| Q3 25 | $24.7M | $60.8M | ||
| Q2 25 | $8.1M | $12.0M | ||
| Q1 25 | $13.8M | $35.5M | ||
| Q4 24 | $9.3M | $33.1M | ||
| Q3 24 | $20.9M | $53.9M | ||
| Q2 24 | $2.2M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $6.2M | $43.5M | ||
| Q3 25 | $18.0M | $57.0M | ||
| Q2 25 | $5.2M | $9.3M | ||
| Q1 25 | $10.6M | $26.9M | ||
| Q4 24 | $4.9M | $31.0M | ||
| Q3 24 | $16.2M | $49.8M | ||
| Q2 24 | $-1.4M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | 22.1% | ||
| Q3 25 | 17.5% | 31.7% | ||
| Q2 25 | 5.1% | 5.1% | ||
| Q1 25 | 9.9% | 15.9% | ||
| Q4 24 | 5.0% | 16.6% | ||
| Q3 24 | 16.1% | 29.6% | ||
| Q2 24 | -1.4% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 7.5% | 0.1% | ||
| Q3 25 | 6.5% | 2.2% | ||
| Q2 25 | 2.8% | 1.5% | ||
| Q1 25 | 3.0% | 5.1% | ||
| Q4 24 | 4.5% | 1.1% | ||
| Q3 24 | 4.6% | 2.4% | ||
| Q2 24 | 3.5% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.15× | — | ||
| Q3 25 | 3.76× | 11.20× | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | 0.66× | 7.37× | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | 0.34× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSV
| Propertyand Merchandise | $47.8M | 45% |
| Cemetery Interment Rights | $24.8M | 23% |
| Merchandise | $18.9M | 18% |
| Other Revenue | $10.2M | 10% |
| Other | $3.9M | 4% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
